Aurin Biotech is developing a collection of small molecule complement-inhibiting agents with the potential to become first-in-class therapies for patients with a wide range of conditions.
| Preclinical |
Phase 1 |
Phase 2 |
Phase 3 |
Approved |
|
|---|---|---|---|---|---|
| AUR1402 | – | – | – | ||
| AUR1103 | – | – | – | – | |
| AUR1104 | – | – | – | – | |
| AUR1105 | – | – | – | – | |
| AUR1106 | – | – | – | – | |
Our lead drug candidate is being developed as the world’s first orally available inhibitor of aberrant complement activation. AUR1402 targets complement protein C9 where it effectively blocks formation of the membrane attack complex (MAC). This makes AUR1402 a promising drug candidate in diseases where pathological activation of the complement cascade is known to occur.